Literature DB >> 28150513

Loss of lean body mass affects low bone mineral density in patients with rheumatoid arthritis - results from the TOMORROW study.

Tadashi Okano1, Kentaro Inui1, Masahiro Tada2, Yuko Sugioka3, Kenji Mamoto1, Shigeyuki Wakitani4, Tatsuya Koike3,5, Hiroaki Nakamura1.   

Abstract

OBJECTIVES: Osteoporosis is one of the complications for patients with rheumatoid arthritis (RA). Rheumatoid cachexia, the loss of lean body mass, is another. However, the relationship between decreased lean body mass and reduced bone mineral density (BMD) in patients with RA has not been well studied.
METHODS: This study included 413 participants, comprising 208 patients with RA and 205 age- and sex-matched healthy volunteers. Clinical data, BMD, bone metabolic markers (BMM) and body composition, such as lean body mass and percent fat, were collected. Risk factors for osteoporosis in patients with RA including the relationship BMD and body composition were analyzed.
RESULTS: Patients with RA showed low BMD and high BMM compared with controls. Moreover, lean body mass was lower and percent fat was higher in patients with RA. Lean body mass correlated positively and percent fat negatively with BMD. Lean body mass was a positive and disease duration was a negative independent factor for BMD in multivariate statistical analysis.
CONCLUSION: BMD and lean body mass were significantly lower in patients with RA compared to healthy controls. Lean body mass correlated positively with BMD and decreased lean body mass and disease duration affected low BMD in patients with RA. TRIAL REGISTRATION: [UMIN Clinical Trials Registry, http://www.umin.ac.jp/ctr/ , UMIN000003876].

Entities:  

Keywords:  Body composition; bone metabolic marker; bone mineral density; rheumatoid arthritis; rheumatoid cachexia

Mesh:

Year:  2017        PMID: 28150513     DOI: 10.1080/14397595.2017.1289645

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  7 in total

1.  Muscle Deficits in Rheumatoid Arthritis Contribute to Inferior Cortical Bone Structure and Trabecular Bone Mineral Density.

Authors:  Joshua F Baker; Jin Long; Sogol Mostoufi-Moab; Michele Denburg; Erik Jorgenson; Prerna Sharma; Babette S Zemel; Elena Taratuta; Said Ibrahim; Mary B Leonard
Journal:  J Rheumatol       Date:  2017-09-15       Impact factor: 4.666

2.  Daily physical activity measured by a wearable activity monitoring device in patients with rheumatoid arthritis.

Authors:  Masahiro Tada; Yutaro Yamada; Koji Mandai; Yoshinari Matsumoto; Noriaki Hidaka
Journal:  Clin Rheumatol       Date:  2022-03-31       Impact factor: 3.650

3.  Association of High Anti-Cyclic Citrullinated Peptide Seropositivity and Lean Mass Index With Low Bone Mineral Density in Rheumatoid Arthritis.

Authors:  Katherine D Wysham; Dolores M Shoback; John B Imboden; Patricia P Katz
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-05-09       Impact factor: 4.794

Review 4.  Practical Management of Cardiovascular Comorbidities in Rheumatoid Arthritis.

Authors:  Roberta Gualtierotti; Nicola Ughi; Giovanni Marfia; Francesca Ingegnoli
Journal:  Rheumatol Ther       Date:  2017-07-27

5.  Osteosarcopenia synergistically increases the risk of falls in patients with rheumatoid arthritis.

Authors:  Masahiro Tada; Yutaro Yamada; Koji Mandai; Yoshinari Matsumoto; Noriaki Hidaka
Journal:  Osteoporos Sarcopenia       Date:  2021-12-04

6.  Improvements in Body Composition after a Proposed Anti-Inflammatory Diet Are Modified by Employment Status in Weight-Stable Patients with Rheumatoid Arthritis, a Randomized Controlled Crossover Trial.

Authors:  Erik Hulander; Helen M Lindqvist; Anna Turesson Wadell; Inger Gjertsson; Anna Winkvist; Linnea Bärebring
Journal:  Nutrients       Date:  2022-03-02       Impact factor: 5.717

Review 7.  Sarcopenia, immune-mediated rheumatic diseases, and nutritional interventions.

Authors:  Alfonso J Cruz-Jentoft; Susana Romero-Yuste; Eugenio Chamizo Carmona; Joan M Nolla
Journal:  Aging Clin Exp Res       Date:  2021-02-10       Impact factor: 3.636

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.